HEMAB THERAPEUTICS HOLDINGS

Hemab Therapeutics shares dip 1.21%, trading near $34.40 with a $1.6B market cap—still showing upside potential and solid liquidity for long‑term investors.

Hemab Therapeutics rallies 3.42% to $34.82, beating peers and signaling fresh pipeline momentum—investors eye a potential upside amid market volatility.

Hemab Therapeutics climbs 3.4% amid modest demand, yet its volatility and lack of dividends raise caution for investors seeking sustainable upside.